Abstract
Oral squamous cell carcinoma (OSCC) is a highly invasive and metastatic tumor, resistant to current multimodal therapies, mirroring therapeutic failure. Therefore, a better understanding of CEO biogenesis's molecular mechanisms is necessary. It is known that the biomolecules of the sphingolipid (SPs) metabolic pathway, such as sphingosine kinases 2 (SK2) and sphingosines-1-phosphate (S1P)…